Internship

Intern – Corporate Development

Confirmed live in the last 24 hours

Cytokinetics

Cytokinetics

501-1,000 employees

Develops drugs for muscle function disorders

Biotechnology
Healthcare

Compensation Overview

$22 - $45Hourly

San Bruno, CA, USA

Work full-time on site from Cytokinetics’ South San Francisco headquarters.

Category
Public Health
Biology Lab & Research
Biology & Biotech
Requirements
  • College or graduate student, with responsibilities tailored accordingly
  • Work full-time on site from Cytokinetics’ South San Francisco headquarters
  • Positive attitude, attention to detail and interest in helping others
  • Team player with strong interpersonal and communication skills
  • Biological knowledge necessary to understand the drug pipeline/portfolio of Cytokinetics and potential partners
  • Excellent analytical capabilities required
  • Ability to summarize or simplify complex concepts in words and graphics and to “think on your feet”
Responsibilities
  • Assist the team responsible for identifying and evaluating licensing and collaboration opportunities and negotiating term sheets and agreements
  • Perform background research on potential partners, including public and proprietary database searches
  • Update internal tracking documents to ensure all information accurately reflects the current situation
  • Support initiatives to enhance alliance management capabilities
  • Inform Cytokinetics’ cross-functional strategic planning
  • Generate and deliver impactful presentations to senior management and key decision-makers

Cytokinetics focuses on developing medicines that improve muscle function for patients with cardiovascular and neuromuscular diseases. Their products are small molecule drugs designed to either enhance or inhibit muscle function, tailored to specific therapeutic needs. The company has a pipeline of drugs, including omecamtiv mecarbil and reldesemtiv, which are in various stages of clinical trials. Unlike many competitors, Cytokinetics emphasizes rigorous scientific research and has conducted over 50 clinical trials to ensure the effectiveness of its treatments. The goal is to bring new therapies to market that address the unmet needs of patients suffering from conditions like heart failure, ALS, and HCM.

Company Stage

IPO

Total Funding

$58.4M

Headquarters

South San Francisco, California

Founded

1998

Growth & Insights
Headcount

6 month growth

2%

1 year growth

1%

2 year growth

14%
Simplify Jobs

Simplify's Take

What believers are saying

  • Cytokinetics secured $575M funding from Royalty Pharma to advance its cardiovascular R&D pipeline.
  • Positive Phase III trial results for aficamten show promise in treating hypertrophic cardiomyopathy.
  • Increased focus on personalized medicine aligns with Cytokinetics' individualized dosing strategies.

What critics are saying

  • Competition from Bristol-Myers Squibb's Camzyos may impact aficamten's market share.
  • Reliance on successful clinical trials poses risks if outcomes are negative.
  • Substantial funding needs indicate financial pressure and dependency on external capital.

What makes Cytokinetics unique

  • Cytokinetics focuses on muscle activators and inhibitors for cardiovascular and neuromuscular diseases.
  • The company targets niche markets like hypertrophic cardiomyopathy and amyotrophic lateral sclerosis.
  • Cytokinetics employs personalized medicine strategies, enhancing individualized dosing for better patient outcomes.

Help us improve and share your feedback! Did you find this helpful?